Recurrent gene fusions in prostate cancer
AssigneesThe Regents of the University of Michigan, The Brigham and Women's Hospital, Inc.
InventorsScott Tomlins, Daniel Rhodes, Arul Chinnaiyan, Rohit Mehra, Mark A. Rubin, Xiao-Wei Sun, Sven Perner, Charles Lee, Francesca Demichelis
Life of this patent
Estimating the term…
Abstract
Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
Claims21
1-26. (canceled)
A composition comprising a hybridized oligonucleotide:target gene fusion duplex, wherein the target gene fusion comprises a chimeric nucleic acid molecule in which a 5′ portion of the chimeric nucleic acid molecule is from a TMPRSS2 gene and a 3′ portion of the chimeric nucleic acid molecule is from an ETS family member gene, wherein the ETS family member gene is selected from the group consisting of ERG, ETV1 (ER81), FLI1, ETS1, ETS2, ELK1, ETV6 (TEL1), ETV7 (TEL2), GABPα, ELF1, ETV4 (E1AF;
- PEA3), ETV5 (ERM), ERF, PEA3/E1AF, PU.1, ESE1/ESX, SAP1 (ELK4), ETV3 (METS), EWS/FLI1, ESE1, ESE2 (ELF5), ESE3, PDEF, NET (ELK3;
- SAP2), NERF (ELF2), and FEV.
A method of producing a hybridized oligonucleotide:target gene fusion duplex, the method comprising contacting a sample comprising a target gene fusion comprising a chimeric nucleic acid molecule in which a 5′ portion of the chimeric nucleic acid molecule is from a TMPRSS2 gene and a 3′ portion of the chimeric nucleic acid molecule is from an ETS family member gene with an oligonucleotide covalently labeled with a detectable label and having a sequence that hybridizes to a junction at which the 5′ portion of the chimeric nucleic acid molecule is fused to the 3′ portion of the chimeric nucleic acid molecule.
Dependencies are inferred from the claim text.